- Home
- About
- Team
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - pharmaceuticals
- UNICHEM LAB - MYLAN (US)
UNICHEM LAB vs MYLAN (US) - Comparison Results
MYLAN (US)
Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More
Financials
 UNICHEM LAB  MYLAN |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| UNICHEM LAB Mar-18 |
MYLAN Dec-14 |
UNICHEM LAB/ MYLAN |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 382 | 4,245 | - | |
| Low | Rs | 234 | 2,992 | - | |
| Sales per share (Unadj.) | Rs | 116.3 | 1,453.3 | - | |
| Earnings per share (Unadj.) | Rs | -18.9 | 175.1 | - | |
| Cash flow per share (Unadj.) | Rs | -11.7 | 281.8 | - | |
| Dividends per share (Unadj.) | Rs | 5.00 | 0 | - | |
| Dividend yield (eoy) | % | 1.6 | 0 | - | |
| Book value per share (Unadj.) | Rs | 381.0 | 722.4 | - | |
| Shares outstanding (eoy) | m | 70.34 | 378.37 | - | |
| Bonus/Rights/Conversions | BB | OI | - | ||
| Price / Sales ratio | x | 2.6 | 2.5 | 106.4% | |
| Avg P/E ratio | x | -16.3 | 20.7 | -78.8% | |
| P/CF ratio (eoy) | x | -26.2 | 12.8 | -204.4% | |
| Price / Book Value ratio | x | 0.8 | 5.0 | 16.1% | |
| Dividend payout | % | -26.4 | 0 | - | |
| Avg Mkt Cap | Rs m | 21,668 | 1,369,126 | 1.6% | |
| No. of employees | `000 | 2.3 | 25.0 | 9.1% | |
| Total wages/salary | Rs m | 2,006 | 0 | - | |
| Avg. sales/employee | Rs Th | 3,587.8 | 21,995.8 | 16.3% | |
| Avg. wages/employee | Rs Th | 880.0 | 0 | - | |
| Avg. net profit/employee | Rs Th | -583.7 | 2,649.8 | -22.0% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 8,180 | 549,896 | 1.5% | |
| Other income | Rs m | 610 | -3,205 | -19.0% | |
| Total revenues | Rs m | 8,790 | 546,690 | 1.6% | |
| Gross profit | Rs m | -1,320 | 136,762 | -1.0% | |
| Depreciation | Rs m | 505 | 40,387 | 1.3% | |
| Interest | Rs m | 80 | 23,720 | 0.3% | |
| Profit before tax | Rs m | -1,295 | 69,449 | -1.9% | |
| Minority Interest | Rs m | 0 | -285 | 0.0% | |
| Prior Period Items | Rs m | -2 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 33 | 2,920 | 1.1% | |
| Profit after tax | Rs m | -1,331 | 66,244 | -2.0% | |
| Gross profit margin | % | -16.1 | 24.9 | -64.9% | |
| Effective tax rate | % | -2.6 | 4.2 | -61.4% | |
| Net profit margin | % | -16.3 | 12.0 | -135.1% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 23,318 | 483,431 | 4.8% | |
| Current liabilities | Rs m | 4,635 | 377,946 | 1.2% | |
| Net working cap to sales | % | 228.4 | 19.2 | 1,190.6% | |
| Current ratio | x | 5.0 | 1.3 | 393.3% | |
| Inventory Days | Days | 122 | 78 | 156.0% | |
| Debtors Days | Days | 121 | 107 | 113.2% | |
| Net fixed assets | Rs m | 8,163 | 127,217 | 6.4% | |
| Share capital | Rs m | 141 | 19,446 | 0.7% | |
| Net worth | Rs m | 26,801 | 273,352 | 9.8% | |
| Long term debt | Rs m | 3 | 408,362 | 0.0% | |
| Total assets | Rs m | 31,890 | 1,101,038 | 2.9% | |
| Interest coverage | x | -15.2 | 3.9 | -386.2% | |
| Debt to equity ratio | x | 0 | 1.5 | 0.0% | |
| Sales to assets ratio | x | 0.3 | 0.5 | 51.4% | |
| Return on assets | % | -3.9 | 8.2 | -48.0% | |
| Return on equity | % | -5.0 | 24.2 | -20.5% | |
| Return on capital | % | -4.5 | 13.6 | -33.3% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | -1,123 | 72,284 | -1.6% | |
| From Investments | Rs m | 16,487 | -57,005 | -28.9% | |
| From Financial Activity | Rs m | -8,811 | -19,047 | 46.3% | |
| Net Cashflow | Rs m | 6,552 | -3,768 | -173.9% | |
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 71.23 Rs / USD
Compare UNICHEM LAB With: ADCOCK INGRAM (S. Africa) ACTAVIS (US) TEVA PHARMA (Israel)
Compare UNICHEM LAB With: IPCA LABS DIVIS LABORATORIES ALEMBIC PHARMA GLENMARK PHARMA NATCO PHARMA
|
| |
Today's Market
Sensex Ends 404 Points Higher; Metal and Oil & Gas Stocks Witness Buying(Closing)
Indian share markets continued their momentum during closing hours and ended the day on a strong note. Gains were largely seen in the metal sector and oil & gas sector.
Related Views On News
UNICHEM LAB Announces Quarterly Results (3QFY19); Net Profit Up 110.9% (Quarterly Result Update)
Feb 4, 2019 | Updated on Feb 4, 2019For the quarter ended December 2018, UNICHEM LAB has posted a net profit of Rs 63 m (up 110.9% YoY). Sales on the other hand came in at Rs 2 bn (up 53.8% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.
UNICHEM LAB Announces Quarterly Results (2QFY19); Net Profit Down 61.4% (Quarterly Result Update)
Nov 5, 2018 | Updated on Nov 5, 2018For the quarter ended September 2018, UNICHEM LAB has posted a net profit of Rs 177 m (down 61.4% YoY). Sales on the other hand came in at Rs 2 bn (down 42.6% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
The Power of 5 Minutes (The 5 Minute Wrapup)
Jun 16, 2017Here's what you can expect from The 5 Minute Wrapup in the coming months and years.
More Views on NewsMost Popular
The RCom Bankruptcy: 5 Lessons for Smallcap Investors(Profit Hunter)
Feb 7, 2019Managements of companies can create or ruin their fortunes. Why is management quality such an important factor in valuing businesses? Read on to find out...
The One Real Estate Stock to Buy Now(The 5 Minute Wrapup)
Feb 13, 2019The real estate sector is ready to make a comeback. This is the stock to consider buying.
How We Pick the Most Profitable Stocks from the Portfolios of Super Investors(The 5 Minute Wrapup)
Feb 8, 2019This is the trick to following super investors and not losing money.
Don't Be Afraid of the Market; Buy Stocks Like This One(The 5 Minute Wrapup)
Feb 14, 2019During this tough period in the market, a contrarian approach holds huge potential upside for this Smart Money Secrets stock.
Small Caps Under Seige: Could This Be A Once-in-a-Decade Wealth Creating Opportunity?(Profit Hunter)
Feb 14, 2019Don't let the dark clouds hovering over small caps scare you into hiding; it will rain gold as sentiments recover. Indeed, there is a blood bath. And if you are a first time investor, the correction is deep enough to scare you out of markets.
More|
| |
UNICHEM LAB SHARE PRICE
Feb 20, 2019 (Close)
TRACK UNICHEM LAB
- Track your investment in UNICHEM LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON UNICHEM LAB
UNICHEM LAB 8-QTR ANALYSIS
COMPARE UNICHEM LAB WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.